Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 17/20 | 0.45 |
| ▸ | CX3CR1 | P49238 | 14/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2110308 | 1.00 | CXCR2 (0.45) | CXCR2CX3CR1ADORA1PAK4 | |
| SCHEMBL10020958 | 0.85 | CXCR2 (0.47) | CXCR2CX3CR1ADORA1PAK4 | |
| SCHEMBL2106415 | 0.82 | CX3CR1 (0.65) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL12022773 | 0.82 | CXCR2 (0.48) | CXCR2CX3CR1 | |
| SCHEMBL1858040 | 0.82 | CXCR2 (0.48) | CXCR2CX3CR1 | |
| SCHEMBL1588550 | 0.76 | CX3CR1 (0.64) | CXCR2CX3CR1ADORA1PAK4 | |
| SCHEMBL1855048 | 0.74 | PAK4 (0.67) | CXCR2CX3CR1PAK4 | |
| SCHEMBL1855744 | 0.71 | CXCR2 (0.37) | CXCR2CX3CR1PAK4 | |
| SCHEMBL1855419 | 0.70 | CXCR2 (0.31) | CXCR2CX3CR1 | |
| SCHEMBL12628897 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035899-A1 | 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035899-A1 | 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | CX3CR1, CCR2, CXCR3 | CXCR2 8/4885CX3CR1 1/4885ADORA1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.